Genmab — Juni 2017
-
Novod kommentarer fra ASCO: All in all, our view on Darzalex data during ASCO is that data looks very strong and should bode well for the first ph III Darzalex frontline data with VMP to be released likely around September. Updated POLLUX and CASTOR data are encouraging too and infusion reaction data is quite intriguing. Lastly, we see increased optimism around the potential immuno-onology properties of Darzalex and hence the potential efficacy in eg solid tumors
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
